Three senior executives at the Association for Accessible Medicines have seen their positions eliminated at the industry body as a result of the latest budgetary measures deployed by the US generics and biosimilars association.
The three affected roles are those of Allen Goldberg, the AAM’s senior vice-president for communications; Erik Komendant, the association’s senior vice-president of government affairs; and Jonathan Kimball, vice-president for trade,...